Bios line Ferplus is a high-dosage Iron supplement in gradual release gastro-resistant tablets. In fact, the gastro-resistant format makes the product without the characteristic Iron taste and preserves from the gastric problems. As well they are often in association with the uptake of this mineral. Additionally, together with the 3 forms of Iron (bisglycinate, pidolate and fumarate), the innovative controlled-release three-stage technology allows its gradual absorption over the whole day. And therefore better use by the body.
In fact, together with Vitamin B12 and Folic Acid, Iron contributes to the formation of red blood cells. Also the reduction of tiredness and fatigue and the normal function of the immune system. Besides, vitamin C increases Iron absorption. Iron is a mineral vital to the proper function of the whole body. However, when there is not enough, tiredness and fatigue are felt.
In fact, lack of iron is one of the most common deficiencies, above all in women of childbearing age, pregnant or breastfeeding and manifests itself with weakness, tiredness and fatigue. Additionally, other conditions of high need are intense sports activity, vegan and vegetarian diets.
So, the iron absorption is greater the more the body needs it. However, you body don’t always absorbs the iron that you take orally so a staggered administration over time may be advantageous, in small quantities to maximize absorption.
How to use Bios line Ferplus?
1 tablet a day with a little water or other liquid, preferably on an empty stomach. Besides, it is useful in case of iron deficiency and in cases of necessary need, such as periods of tiredness in general, during the menstrual cycle or pregnancy and while breastfeeding.
Bios line Ferplus 60 capsules
$27.60 Original price was: $27.60.$25.00Current price is: $25.00.
SKU: 902525942
Category: Korean cosmetic
Be the first to review “Bios line Ferplus 60 capsules” Cancel reply
Related products
Sale!
Korean cosmetic
Sale!
Korean cosmetic
Sale!
Korean cosmetic





Reviews
There are no reviews yet.